Home
Blog
Medication & Safety
Ozempic vs Wegovy: What Is the Difference?

Ozempic vs Wegovy: What Is the Difference?

Ayesha Tariq, Medical Content Writer July 8, 2026 · 4 min read

Medically reviewed Dr. Saad Mahmood MBBS, FCPS (Endocrinology)

Ozempic and Wegovy contain the same molecule — semaglutide. The difference is dose, approval, and cost. Here is what that means for weight loss results.

Ozempic and Wegovy are the same drug. Both contain semaglutide, the GLP-1 receptor agonist made by Novo Nordisk. A person injecting Ozempic and a person injecting Wegovy are putting the same molecule into their body. What differs is the dose, the approved indication, and the cost.

This distinction matters because many people assume they are choosing between two different medications when the real choice is between two dose levels of the same one.

The Molecule Is Identical

Semaglutide is the active ingredient in both Ozempic and Wegovy. It was developed as a once-weekly GLP-1 receptor agonist for type 2 diabetes management. During diabetes trials, patients lost weight consistently and significantly — which led Novo Nordisk to test higher doses specifically for obesity treatment.

Wegovy is the higher-dose formulation of exactly the same molecule that went through diabetes approval as Ozempic. The chemistry is identical.

The Dose Difference

This is the meaningful difference. Ozempic is available in doses of 0.5 mg, 1 mg, and 2 mg weekly. The standard maximum dose prescribed for diabetes is 1 mg to 2 mg.

Wegovy is approved at a maximum dose of 2.4 mg weekly — the highest dose studied in the STEP trial programme. The weight loss results from the STEP trials (14.9% average weight reduction over 68 weeks) were achieved at this 2.4 mg dose.

Physicians who prescribe Ozempic off-label for weight loss often use 1 mg or 2 mg. Some prescribe up to 2.4 mg, effectively using Ozempic at Wegovy's dose. The drug's pharmacology does not change — the difference is only in what the regulatory approval specifies.

The Approval Difference

Ozempic is approved by the FDA, EMA, and other regulatory bodies for type 2 diabetes management. Its weight loss benefits are documented but the drug is approved for glycaemic control.

Wegovy received FDA approval in 2021 specifically for chronic weight management in adults with obesity (BMI over 30) or overweight (BMI over 27) with at least one weight-related condition. This specific weight management approval matters for insurance coverage in markets where that applies.

The Weight Loss Results

At equivalent doses, the drugs produce equivalent results. At 2.4 mg, participants in the STEP 1 trial (Wegovy studies) lost an average of 14.9% of body weight over 68 weeks.

Ozempic prescribed off-label for weight loss at 1 mg typically produces five to eight percent body weight reduction. At 2 mg, results approach ten percent. The dose is the primary driver of outcomes.

Cost and Availability

In markets where both are available, Wegovy is typically priced higher than Ozempic. This has created a common situation where patients prescribed Wegovy instead use Ozempic at the same 2.4 mg dose, because it is more available and sometimes less expensive.

Neither drug is officially registered with DRAP in Pakistan. Both face the same access challenges for Pakistani patients.

For Pakistani Patients

For most Pakistani readers, the Ozempic vs. Wegovy question is academic — neither is officially registered in Pakistan. The accessible option is METASLIM: a DRAP-registered GLP-1 sublingual supplement that targets the same receptor pathway as both drugs, delivered as drops under the tongue rather than a weekly injection. It is physician-guided, available nationwide, and fits within a structured 8-week program.

Physician-Guided Program

Ready to work with your hunger hormones, not against them?

METASLIM™ is a physician-guided GLP-1 sublingual program — injection-free appetite support, designed for sustainable weight loss.

Order METASLIM™ →

Frequently Asked Questions

Yes. Both contain semaglutide — the same molecule at the same purity. The difference is the approved maximum dose: Ozempic goes to 2 mg for diabetes; Wegovy goes to 2.4 mg for obesity. At equivalent doses, they produce equivalent effects.

Wegovy produces greater average weight loss because it is approved at a higher dose (2.4 mg vs. 2 mg maximum for Ozempic). The STEP 1 trial at 2.4 mg showed 14.9% average body weight reduction. At lower Ozempic doses, weight loss is proportionally lower.

Yes. Physicians routinely prescribe Ozempic off-label for weight loss. Some prescribe it at doses up to 2.4 mg — identical to Wegovy's maximum dose. The choice often comes down to insurance coverage, cost, and supply availability.

Both are brand-name products from Novo Nordisk. Wegovy's specific obesity indication and its higher dose make it priced differently in many markets. Supply shortages have also created price variability. In practice, many patients use Ozempic instead because it is more available.

Yes, because the drug is the same. Nausea, constipation, and other GI effects occur at similar rates. Higher doses produce more pronounced side effects during escalation, which is why Wegovy's dose escalation protocol takes 16 weeks to reach 2.4 mg.

Neither is officially registered with DRAP. Some informal imports exist through private pharmacies in major cities but without regulatory oversight or guaranteed authenticity. Pakistani patients seeking GLP-1 pathway support should explore DRAP-registered options. The Ozempic vs. Wegovy choice ultimately comes down to dose access and approval context. Understanding that they are the same drug at different doses removes the confusion and puts the focus where it belongs: on the dose, the adherence, and the lifestyle changes that determine how well semaglutide works for any individual. *This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.*

Written by

Ayesha Tariq

Medical Content Writer

Ayesha is a Karachi-based health writer specialising in metabolic health and evidence-based nutrition for South Asian readers.

Medically reviewed by

Dr. Saad Mahmood

MBBS, FCPS (Endocrinology)

Dr. Mahmood is a consultant endocrinologist with a decade of experience managing obesity and type 2 diabetes.

← Back to Health Blog Start the Program →